X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Merck Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs MERCK LTD - Comparison Results

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES MERCK LTD VENUS REMEDIES/
MERCK LTD
 
P/E (TTM) x -8.9 48.8 - View Chart
P/BV x 0.1 6.4 2.2% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 VENUS REMEDIES   MERCK LTD
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
MERCK LTD
Dec-16
VENUS REMEDIES/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs1431,060 13.5%   
Low Rs65623 10.4%   
Sales per share (Unadj.) Rs324.2632.4 51.3%  
Earnings per share (Unadj.) Rs6.445.7 14.0%  
Cash flow per share (Unadj.) Rs40.662.3 65.1%  
Dividends per share (Unadj.) Rs011.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs366.0388.8 94.1%  
Shares outstanding (eoy) m12.3416.60 74.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.31.3 24.1%   
Avg P/E ratio x16.218.4 88.1%  
P/CF ratio (eoy) x2.613.5 19.0%  
Price / Book Value ratio x0.32.2 13.1%  
Dividend payout %024.1 0.0%   
Avg Mkt Cap Rs m1,28213,969 9.2%   
No. of employees `0000.91.6 57.0%   
Total wages/salary Rs m2511,487 16.9%   
Avg. sales/employee Rs Th4,430.16,631.9 66.8%   
Avg. wages/employee Rs Th278.0939.2 29.6%   
Avg. net profit/employee Rs Th87.6479.4 18.3%   
INCOME DATA
Net Sales Rs m4,00010,498 38.1%  
Other income Rs m23242 9.4%   
Total revenues Rs m4,02310,741 37.5%   
Gross profit Rs m7851,135 69.1%  
Depreciation Rs m422276 153.0%   
Interest Rs m3440-   
Profit before tax Rs m421,102 3.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-37343 -10.8%   
Profit after tax Rs m79759 10.4%  
Gross profit margin %19.610.8 181.4%  
Effective tax rate %-87.931.1 -282.2%   
Net profit margin %2.07.2 27.4%  
BALANCE SHEET DATA
Current assets Rs m2,6066,410 40.7%   
Current liabilities Rs m1,9808,828 22.4%   
Net working cap to sales %15.6-23.0 -67.9%  
Current ratio x1.30.7 181.3%  
Inventory Days Days12858 222.4%  
Debtors Days Days4338 112.4%  
Net fixed assets Rs m5,3531,406 380.6%   
Share capital Rs m123166 74.3%   
"Free" reserves Rs m4,3936,286 69.9%   
Net worth Rs m4,5166,455 70.0%   
Long term debt Rs m1,6180-   
Total assets Rs m8,2918,828 93.9%  
Interest coverage x1.1NM-  
Debt to equity ratio x0.40-  
Sales to assets ratio x0.51.2 40.6%   
Return on assets %5.18.6 59.3%  
Return on equity %1.811.8 14.9%  
Return on capital %6.317.1 36.8%  
Exports to sales %08.3 0.0%   
Imports to sales %18.421.0 87.5%   
Exports (fob) Rs mNA869 0.0%   
Imports (cif) Rs m7362,209 33.3%   
Fx inflow Rs m0959 0.0%   
Fx outflow Rs m7362,612 28.2%   
Net fx Rs m-736-1,653 44.5%   
CASH FLOW
From Operations Rs m9971,070 93.2%  
From Investments Rs m-461-750 61.5%  
From Financial Activity Rs m-571-150 381.2%  
Net Cashflow Rs m-35171 -20.5%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 0.2 18.2 1.0%  
FIIs % 0.6 1.0 58.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 29.1 228.2%  
Shareholders   20,121 28,591 70.4%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  ALEMBIC PHARMA  AJANTA PHARMA  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2%

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jun 22, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - WOCKHARDT LTD. COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS